Our Background

Excellence built from a unique heritage

Today, Beactica Therapeutics is setting the pace in the cancer drug development landscape, with a strong focus on leveraging synthetic lethality to develop novel therapeutics for genetically defined cancers. This position at the forefront of the field, is rooted in Beactica’s unique heritage spanning decades of research and industrial development.

2006

Beactica is founded in Uppsala by Dr Per Källblad and Prof. Helena Danielson to pioneer fragment-based drug discovery using SPR biosensor technology

2010

Beactica delivers key insights to Boehringer Ingelheim on the molecular interactions between cancer drug Afatinib (Giotrif®) and its cellular targets

2011

Beactica's FBLG platform enables the generation of TAK-831, a highly selective and potent inhibitor of D-amino acid oxidase (DAAO), that Takeda progresses to phase II trials in schizophrenia

2013

Beactica's FBLG platform enables the generation of the world's first highly potent and selective allosteric USP7 inhibitor that later is outlicensed by Almac to Genentech in a deal worth $363 million

2014

Beactica initiates pilot work on an internal drug pipeline and closes its first financing round

2015

Beactica and Janssen publish in PNAS on the identification of novel allosteric modulators for the alpha7 nicotinic acetylcholine receptor, further validating Beactica's FBLG platform

2016

Beactica and Dong-A ST enter into license and collaboration agreement to develop novel cancer therapies targeting a family of epigenetic enzymes

2019

Beactica Therapeutics and Dong-A ST achieve a key milestone in their anti-cancer collaboration when a first-in-class protein–protein interaction inhibitor meets certain pre-defined lead criteria

2019

Beactica changes name to Beactica Therapeutics to highlight the company's strategic focus on developing an internal pipeline of candidate drugs

2022

Beactica Therapeutics aims its focus on leveraging synthetic lethality to tackle genetically defined cancers, with a vision to become a clinical-stage precision oncology company

2022

Beactica Therapeutics gains full ownership of prioritised YAP–TEAD assets and add programme to its pipeline

2023

Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma

2023

Beactica Therapeutics announces collaboration on TEAD with the National Center for Advancing Translational Sciences at NIH

2024

Beactica's Eclipsor™ platform for developing proteolysis-targeting protein degraders (TPDs/PROTACs) achieves in vivo validation.

This exceptional track record – in combination with the team's dedication to scientific excellence – showcases Beactica ability to steadily advance its position in the pharmaceutical R&D value chain. 

Today, our vision is to become a clinical-stage precision oncology company with a pipeline of breakthrough therapeutics against genetically defined cancers. 

Read more about our pipeline here.

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates